Deferiprone

別名：CP20

製品コード：S4067 純度：99.97%

Deferiprone (CP20) is a chelating agent with an affinity for ferric ion (iron III)，binds with ferric ions to form neutral 3:1 (deferiprone:iron) complexes that are stable over a wide range of pH values.

CAS No. 30652-11-0

サイズ	価格(税別)	在庫状況
50mg	JPY 22000	国内在庫あり
1g	JPY 70500	国内在庫あり

代表番号: 045-509-1970\|電子メール：[email protected] よく尋ねられる質問

文献中Selleckの製品使用例（14）

製品安全説明書

現在のバッチを見る：純度： 99.97%

99.97

Deferiprone関連製品

関連製品	BAPTA-AM Rat IgG2b isotype control-InVivo Blebbistatin Methyl-β-cyclodextrin (MβCD) AP-III-a4 (ENOblock) Carbazochrome sodium sulfonate (AC-17) Ursolic Acid Osthole NAD+ 4-Methylumbelliferone (4-MU) Dioscin Ethidium bromide Pitstop 2 Sesamin Bilobalide Formononetin Hesperidin Palmitic acid Azeliragon (TTP488) L-Mimosine Ademetionine Carbenoxolone Sodium GO-203 Vitexin N6022 Dp44mT Chlorogenic Acid Sphingosine Chrysin Coenzyme Q10 (CoQ10) Spermine Tetrahydrochloride 2-NBDG 2-NBDG D-Lin-MC3-DMA (MC3) Morin Hydrate Ethylenediaminetetraacetic acid Silibinin (NSC 651520) (+)-Fangchinoline Bergenin Spermine NB 598 DMNQ (20S)Ginsenoside Rg2 Farrerol EGCG Octaacetate D-(+)-Trehalose dihydrate Reboxetine mesylate E7820 MYLS22 Hydroxytyrosol Evofosfamide (TH-302) Bromhexine HCl 5-hydroxytryptophan (5-HTP) Inosine D-Mannose Anethole trithione Sodium Nitroprusside Dihydrate Alendronic Acid 2,4-Pyridinedicarboxylic acid GSK805 ADP Acipimox Curcumin analog C1 Trimetazidine 2,2,2-Tribromoethanol N-Acetylneuraminic acid Quinacrine Dihydrochloride Dihydrate L-methionine Stigmasterol Oleanonic Acid Substance P TFA Ginsenoside Rg3 NSI-189 SR8278 Lycopene Trometamol hydrochloride 1-Methyl-3-nitro-1-nitrosoguanidine (MNNG) Ureidosuccinic acid Tea polyphenol Fructose (+)-JQ1 carboxylic acid Ligustilide Polybrene (Hexadimethrine Bromide) Pinoresinol diglucoside 4-HNE (4-Hydroxynonenal) Iron Dextran Sodium Picosulfate IM-54 Disufenton sodium Troxipide Orcinol glucoside Diludine 20R-Camptothecin (+)-Usniacin 3-Indolebutyric acid (IBA) HEPES Cremophor EL BMS-986176 DTT (Dithiothreitol) Esculin Methyl Eugenol Polyinosinic acid-polycytidylic acid L-(-)-Glucose 1-Hydroxy-2-naphthoic acid Azomycin 3-Hydroxybenzoic acid Emlenoflast (MCC-7840) β-Alanine β-Sitosterol Rat IgG1 isotype control-InVivo Aminomalonic acid Helecin BRM/BRG1 ATP Inhibitor-1 23-Hydroxybetulinic acid PZ-2891 Toosendanin 1,2-Propanediol Epibrassinolide Cyanidin-3-O-glucoside chloride Dihydrotanshinone I Gracillin Sodium Pyruvate Itaconic acid FH1 Cinnamic acid Guanidine HCl Triethylenetetramine 2HCl Molsidomine Calcium D-saccharate tetrahydrate Creatine monohydrate DL-Dopa FPH1 5'-Adenylic acid Acetamide ML329 Pterostilbene Kinetin Acetyl Resveratrol GSK4112 LTI-291 Plantamajoside Anhydroicaritin BZ1 Phloretic acid Anemoside B4 EGTA Sucralose 6-Chloropurine Glucosamine hydrochloride Sinoacutine 2,4-Dihydroxyacetophenone Stearic acid Stevioside Morin PMPA tetrasodium salt L-Hydroorotic acid Irigenin Behenic Acid CTX-0294885 Fudosteine (R)-(-)-JQ1 Enantiomer 2'-Deoxyguanosine monohydrate L-Tryptophanamide Hydrochloride β-Cyclodextrin 3-Indolepropionic acid DL-Citrulline Sclareol Methyl protocatechuate Sodium nitroprusside N-Nitrosodiethylamine Deoxyaconitine N-Acetyl-L-methionine Sinapine thiocyanate Sodium succinate Senkyunolide A L-Tryptophan Swertiamarin Octyl gallate Brassinazole	もっと見る
関連化合物ライブラリー	FDA-approved Drug Library Natural Product Library Bioactive Compound Library-I Express-Pick Library	もっと見る

生物活性

製品説明	Deferiprone (CP20) is a chelating agent with an affinity for ferric ion (iron III)，binds with ferric ions to form neutral 3:1 (deferiprone:iron) complexes that are stable over a wide range of pH values.
特性	Possesses 10-fold higher cytotoxicity than maltol in both HL-60 and HSC-2 cell lines.

In Vitro
In vitro	Deferiprone (100 μM) is able to protect myocytes from doxorubicin-induced lactate dehydrogenase release. Deferiprone (300 μM) quickly and efficiently removes iron(III) from its complex with doxorubicin. Deferiprone (300 μM) rapidly enters myocytes and displaces iron from a fluorescence-quenched trapped intracellular iron-calcein complex, suggesting that in the myocyte, deferiprone should also be able to displace iron from its complex with doxorubicin. Deferiprone (3 mM) also greatly reduces hydroxyl radical production by the iron(III)-doxorubicin complex in the xanthine oxidase/xanthine superoxide generating system. ^[1] Deferiprone (0.5 mM) increases removal of RBC membrane free iron in a time and dose dependent manner. ^[2] Deferiprone (0.3 mM) is effective in inhibiting radioactive iron mobilization from iron-loaded heart cells and protecting or restoring mitochondrial respiratory enzyme activity. Deferiprone (1 mM) results in a sharp decrease in complex I-III activity in iron-loaded heart cells. ^[3] Deferiprone shows cytotoxic effect of human tumor cell lines HSC-2, HSC-3 and HL-60 with IC50 of 13.5 μg/mL, 9.9 μg/mL and 10.6 μg/mL, the cytotoxic activity of HK1 against HL-60 and HSC-2 cells is reduced in the presence of FeCl₃. Deferiprone (100 μg/mL) induces internucleosomal DNA fragmentation in HL-60 cells, but the addition of FeCl₃ inhibits the DNA fragmentation. Deferiprone (100 μg/mL) activates the caspase 3, 8 and 9 in HSC-2 cells. ^[4]

In Vivo
In Vivo	Deferiprone (100 mg/kg) reduces the mean basilar artery cross-sectional areas by 24% in rabbits. Deferiprone (100 mg/kg) combined with subarachnoid hemorrhage(SAH) shows a variable amount of corrugation of the internal elastic lamina in rabbits. ^[5]

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
臨床試験 (data from https://clinicaltrials.gov, updated on 2024-05-22)
NCT02878538	Withdrawn	Mild Cognitive Impairment	The University of Texas Health Science Center at San Antonio	January 2018	Early Phase 1
NCT02728843	Completed	Parkinson''s Disease	ApoPharma\|Chiesi Canada Corp	October 12 2016	Phase 2
NCT02477631	Completed	Myelodysplastic Syndrome With Low-grade Lesions\|Iron Overload Due to Repeated Red Blood Cell Transfusions	Sheba Medical Center\|Hadassah Medical Organization\|Tel Aviv Medical Center\|Kaplan Medical Center\|Ziv Medical Center	February 2016	Phase 2

参考
[1] Barnab?N, et al. Free Radic Biol Med, 2002, 33(2), 266-275. [2] Shalev O, et al. Blood, 1995, 86(5), 2008-2013. [3] Link G, et al. J Lab Clin Med, 1999, 133(2), 179-188. [4] Yasumoto E, et al. Anticancer Res, 2004, 24(2B), 755-762. [5] Arthur AS, et al. Neurosurgery, 1997, 41(6), 1385-1391. + 展開

参考

+ 展開

化学情報

分子量	139.15	化学式	C₇H₉NO₂
CAS No.	30652-11-0	SDF	Download Deferiprone SDFをダウンロードする
Smiles	CC1=C(C(=O)C=CN1C)O
保管	3年-20°C粉	溶液の保管冷凍と解凍の繰り返しを避けるため小分けにしてください	1年-80°Cin solvent
保管	3年-20°C粉	溶液の保管冷凍と解凍の繰り返しを避けるため小分けにしてください	1个月-20°Cin solvent

In vitro
Batch:

Water : 27 mg/mL

DMSO : Insoluble ( 吸湿したDMSOは溶解度を減少させます。新しいDMSOをご使用ください。)

Ethanol : Insoluble

モル濃度計算器

in vivo
Batch:

Add solvents to the product individually and in order.

投与溶液組成計算機

実験計算

モル濃度計算器

質量	濃度	体積	分子量
=	×	×

希釈計算器分子量計算器

投与溶液組成計算機(クリア溶液)

ステップ１：実験データを入力してください。（実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します）

投与量 mg/kg 動物平均体重 g 投与体積（動物毎）μL 動物数匹

ステップ２：投与溶媒の組成を入力してください。（ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください）

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

計算結果：

投与溶媒濃度： mg/ml;

DMSOストック溶液調製方法： mg 試薬を μL DMSOに溶解する（濃度 mg/mL, 注：濃度が当該ロットのDMSO溶解度を超える場合はご連絡ください。 )

投与溶媒調製方法：Take μL DMSOストック溶液に μL PEG300，を加え、完全溶解後μL Tween 80，を加えて完全溶解させた後 μL ddH₂O，を加え完全に溶解させます。

投与溶媒調製方法：μL DMSOストック溶液に μL Corn oil，を加え、完全溶解。

注意：１.ストック溶液に沈殿、混濁などがないことをご確認ください；
２.順番通りに溶剤を加えてください。次のステップに進む前に溶液に沈殿、混濁などがないことを確認してから加えてください。ボルテックス、ソニケーション、水浴加熱など物理的な方法で溶解を早めることは可能です。

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須

* 大学・企業名 大学・企業名を記入してください

* 名前 名前を記入してください

* 電子メール 電子メール・アドレスを記入してください 有効なメールアドレスを入力してください

電話番号

* 内容 お問い合わせ内容をご入力ください

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):